

# Protocol-Specified Rash Severity Grading


- **Grade 1**
  - Localized skin eruption
- **Grade 2**
  - Diffuse skin eruption up to 50% of the body surface area (BSA)
- **Grade 3**
  - Generalized skin eruption involving  $> 50\%$  BSA, or
  - Rash with bullae, vesicles, mucous membrane ulceration, target lesions, purpura, or with epidermal detachment

# Frequency of Resistance Profiles in Patients Who Did Not Achieve an SVR

## Phase 3 Studies

Variant	% of sequenced patients	
	Subtype 1a	Subtype 1b
WT	16	46
V36M	10	3
R155K	20	0
V36M+R155K	46	0
V36A	3	16
T54A	< 1	22
A156S/T	3	13

# Resistance Profile in Patients Who Did Not Achieve an SVR With or Without Lead-In Study C216—by Failure Type



# Skin Rash

## Patients on Telaprevir + Peg-IFN/RBV

### Phase 3 Studies



P-



Mild (localized)

Moderate (<50% BSA)

Severe (>50% BSA)



93.4% of all rash events were  
of mild or moderate severity



6.5% of all rash  
events

# Labeling, Communication, and Education Measures

## Rash

- **Labeling**
  - Warnings for severe rash
  - Alerts to monitoring all rashes for progression
  - Lists mild and moderate rash as ADR
- **Communication**
  - Patients—alerts patients to connect with HCP, not to discontinue on their own
  - HCPs—communicates to HCPs importance of monitoring rashes for progression, how to identify a severe rash, and when to stop telaprevir
- **Medical Education**
  - Appropriate education to HCPs on rash associated with telaprevir/PR in patients with chronic HCV
  - Multiple forums


# Labeling, Communication and Education Measures

## Anemia

- **Labeling**
  - Warnings for anemia
  - Alerts to monitoring hemoglobin
  - Provides pattern of hemoglobin decrease and recovery, incidence of ESA use, RBV dose modification, and other relevant information
  - Lists also as an ADR
- **Communication**
  - Patients—alerts patients to connect with HCP if experiencing potential anemia signs and symptoms, HCPs will check blood regularly for anemia and other possible blood problems
  - HCP—communicates to HCPs importance of monitoring hemoglobin for worsening and reinforces management strategies
- **Medical Education**
  - Appropriate education to HCPs on anemia associated with telaprevir/PR in patients with chronic HCV
  - Multiple forums

# PK Profiles for R-Methadone Study C135

Mean (SD) Plasma Concentration-Time  
Curves of R-Methadone



### Effect on R-Methadone

- $C_{max}$  0.71 (0.66; 0.76)
- AUC 0.71 (0.66; 0.76)
- $C_{min}$  0.69 (0.64; 0.75)